ISSN: 2157-7609
+44-77-2385-9429
Kazim Husain
Department of Physiology, Pharmacology and Toxicology, Ponce School of Medicine and Health Sciences, P O Box 7004, Ponce, PR 00732,
Tanzania
Review Article
Pancreatic Cancer Treatment
Author(s): Kazim Husain
Kazim Husain
Pancreatic canceris one of the most aggressive and lethal human cancers, with more than 200, 000 deaths worldwide every year. Despite recent efforts, conventional treatment approaches, such as surgery, classic chemotherapy, radiotherapy, biologic therapy and palliative care have only slightly improved patient outcomes. Among the conventional chemotherapies the combination of abraxane (nab-paclitaxel) with gemcitabine and FOLFIRINOX (5-FU/leucovorin, irinotecan, and oxaliplatin) with gemcitabine in metastatic pancreatic cancer patients are promising. Among the targeted therapies the combination of gemcitabine, erlotinib and capecitabine are likely to form the base for future treatment. Under biologic or immunotherapy KRAS-targeting vaccines, telomerase-targeting vaccine (GV1001), gastrin-based vaccine, dendritic cell (DC)-based vaccine alone or combined with lymphokineactivated killer (LA.. View More»
DOI:
10.4172/2157-7609.1000162